Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Annals of Surgical Oncology|December 4, 2018
Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?Jennifer L Baker, Shirin Muhsen, Emily C Zabor, et al.
Cancer|June 18, 2019
Does race predict survival for women with invasive breast cancer?Siún M Walsh, Emily C Zabor, Michelle Stempel, et al.
Cancer|February 8, 2008
Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?Sarah A McLaughlin, Michelle Stempel, Elizabeth A Morris, et al.
Annals of Surgical Oncology|January 29, 2017
Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?Andrea V Barrio, Anita Mamtani, Anne Eaton, et al.
Gynecologic Oncology|December 23, 2008
Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary massAmer K Karam, Michelle Stempel, Richard R Barakat, et al.
Annals of Surgical Oncology|August 2, 2017
The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor SubtypeMelissa Pilewskie, Emily C Zabor, Anita Mamtani, et al.
Annals of Surgical Oncology|May 14, 2016
Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?Melissa Pilewskie, Michelle Stempel, Hope Rosenfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2011
Clinical management factors contribute to the decision for contralateral prophylactic mastectomyTari A King, Rita Sakr, Sujata Patil, et al.
Annals of Surgical Oncology|September 17, 2017
Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast CancerLori F Gentile, George Plitas, Emily C Zabor, et al.
Annals of Surgical Oncology|August 29, 2019
Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines?Anita Mamtani, Emily C Zabor, Laura H Rosenberger, et al.
Pageof 7